Long lasting drug formulations
First Claim
1. A long-lasting therapeutic formulation for implanting into an immunocompetent human subject comprising a genetically modified dermal micro-organ, wherein said micro-organ is transduced in vitro with a helper-dependent adenoviral (HdAd) vector or with an adeno-associated viral (AAV) vector comprising a nucleic acid sequence encoding a therapeutic erythropoietin polypeptide operably linked to one or more regulatory sequences, wherein said nucleic acid sequence is greater than 95% homologous to SEQ ID No:
- 1, wherein following said transduction in vitro expression of said therapeutic polypeptide is determined, and wherein implantation of said long-lasting formulation in said immunocompetent human subject provides a beneficial effect selected from the group consisting of;
a. an increase in expression levels of said therapeutic erythropoietin in the subject'"'"'s serum compared with pre-implantation basal levels; and
b. an alleviation of a symptom of a disease or disorder in said subject, wherein said alleviation persists for greater than one month.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha.
-
Citations
8 Claims
-
1. A long-lasting therapeutic formulation for implanting into an immunocompetent human subject comprising a genetically modified dermal micro-organ, wherein said micro-organ is transduced in vitro with a helper-dependent adenoviral (HdAd) vector or with an adeno-associated viral (AAV) vector comprising a nucleic acid sequence encoding a therapeutic erythropoietin polypeptide operably linked to one or more regulatory sequences, wherein said nucleic acid sequence is greater than 95% homologous to SEQ ID No:
- 1, wherein following said transduction in vitro expression of said therapeutic polypeptide is determined, and wherein implantation of said long-lasting formulation in said immunocompetent human subject provides a beneficial effect selected from the group consisting of;
a. an increase in expression levels of said therapeutic erythropoietin in the subject'"'"'s serum compared with pre-implantation basal levels; and b. an alleviation of a symptom of a disease or disorder in said subject, wherein said alleviation persists for greater than one month. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
- 1, wherein following said transduction in vitro expression of said therapeutic polypeptide is determined, and wherein implantation of said long-lasting formulation in said immunocompetent human subject provides a beneficial effect selected from the group consisting of;
Specification